Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.51 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | CTSG | P08311 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29415192 | 1.00 | MAOB (0.57) | MAOBPDCD1CD274PDE4APDE4B | |
| Vanillyl Alcohol SCHEMBL10533321 | 0.85 | MAOB (0.61) | MAOBCYP3A4GAATSHRMAPK1 | |
| SCHEMBL6297020 | 0.85 | MAOB (0.59) | MAOBMAPTCYP3A4APPESR1 | |
| SCHEMBL9862162 | 0.84 | MAOB (0.53) | MAOBMAPTCYP3A4APPESR1 | |
| SCHEMBL4847162 | 0.83 | MAOB (0.52) | MAOBPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8296534 | 0.83 | MAOB (0.57) | MAOBMAPTCYP3A4APPESR1 | |
| SCHEMBL13318421 | 0.83 | MAOB (0.57) | MAOBMAPTCYP3A4APPESR1 | |
| SCHEMBL23671876 | 0.82 | MAOB (0.55) | MAOBMAPTCYP3A4APPESR1 | |
| SCHEMBL772479 | 0.82 | MAOB (0.55) | MAOBMAPTCYP3A4APPESR1 | |
| SCHEMBL5216474 | 0.82 | MAOB (0.55) | MAOBMAPTCYP3A4APPESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1341503-B1 | AGENT AND METHOD FOR DYEING KERATIN FIBRES | WELLA AG (DE) | 2008-02-13 | — | — | EP | claimed |
| US-6835212-B2 | Compound with a nucleophilic reaction center, aryl alcohol or benzyl alcohol derivatives and an oxidizing enzyme | WELLA AKTIENGESELLSCHAFT (DE) | 2004-12-28 | — | — | US | claimed |
| EP-1341503-A2 | AGENT AND METHOD FOR DYEING KERATIN FIBRES | Wella Aktiengesellschaft (DE) | 2003-09-10 | — | — | EP | claimed |
| US-20030041391-A1 | Agent and method for dyeing keratin fibres | Wella GmbH (DE) | 2003-03-06 | — | — | US | claimed |
| WO-2002047633-A2 | AGENT AND METHOD FOR DYEING KERATIN FIBRES | WELLA AKTIENGESELLSCHAFT (DE) | 2002-06-20 | — | — | WO | claimed |
| US-5726243-A | Mild solid-phase synthesis of aligned, branched triple-helical peptides | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1998-03-10 | — | — | US | claimed |
| US-5576419-A | Mild solid-phase synthesis of aligned branched triple-helical peptides | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1996-11-19 | — | — | US | claimed |
| EP-0292729-B1 | PROCESS FOR SOLID PHASE PEPTIDE SYNTHESIS | BACHEM AG (CH) | 1992-04-22 | — | — | EP | claimed |
| EP-0292729-A2 | Process for solid phase peptide synthesis | BACHEM AG (CH) | 1988-11-30 | — | — | EP | claimed |
| US-20260103498-A1 | METHOD FOR PREPARING LIRAGLUTIDE | BACHEM HOLDING AG (CH) | 2026-04-16 | — | — | US | disclosed |
| CN-119032076-A | Novel compounds and uses thereof | 株式会社安提昂 | 2024-11-26 | — | — | CN | disclosed |
| EP-4345104-B1 | METHOD FOR PREPARING LIRAGLUTIDE | BACHEM HOLDING AG (CH) | 2024-08-28 | — | — | EP | disclosed |
| CN-118043339-A | Antimicrobial peptidomimetics | 巴斯利尔药物阿尔施维尔国际股份公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2024068827-A1 | METHOD FOR PREPARING LIRAGLUTIDE | BACHEM HOLDING AG (CH) | 2024-04-04 | — | — | WO | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4914151-A | Resin-linker combination for the solid-phase synthesis of peptides and intermediates | BACHEM FEINCHEMIKALEIN A.G. (CH) | 1990-04-03 | — | — | US | disclosed |
| US-4831084-A | Resin-linker combination for the solid-phase synthesis of peptides and intermediates | BACHEM FEINCHEMIKALIEN A.G. (CH) | 1989-05-16 | — | — | US | disclosed |
| EP-0292729-A2 | Process for solid phase peptide synthesis | BACHEM AG (CH) | 1988-11-30 | — | — | EP | disclosed |
| US-4778757-A | ADDING FIRST REAGENT OF OXIDASE, PEROXIDASE AND PHENOLIC CHROMOGEN FOLLOWED BY ADDING COUPLER; ACCURATE COLORIMETRY | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 1988-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103498-A1 | METHOD FOR PREPARING LIRAGLUTIDE | GLP1R, IAPP, VIP | MAOB 3979/4885PDCD1 2137/4885CD274 2715/4885 |
| US-20030041391-A1 | Agent and method for dyeing keratin fibres | KRT18, AKR7A2, ADH5 | MAOB 107/4885PDCD1 3400/4885CD274 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.